We have read with interest the paper by Gerbes et al ,1 which highlights the current developments in the treatment of hepatocellular carcinoma (HCC). Fibrolamellar HCC (FL-HCC) is, in contrast to HCC,2 an infrequent tumour, most often occurring in adolescents or young adults without underlying liver disease.3 Chemotherapy-based regimens are typically used to treat FL-HCC based on studies in small patients’ cohorts and case series.3 Despite anecdotal reports of response to systemic treatment, the prognosis of advanced FL-HCC is poor.4 The development of immune checkpoint inhibitors (ICP) is drastically changing the approach to the treatment of HCC. In particular, recent trials showed that immunoncological treatment can be potentiated if ICP are used in combination.5 6 This is exemplified by the use of nivolumab/ipilimumab,7 and by the results of the phase III IMBRAVE 150 trial, which recently marked …

中文翻译：

---

使用双重检查点阻断治疗纤维板层肝细胞癌

我们饶有兴趣地阅读了 Gerbes 等人 1 的论文，其中重点介绍了肝细胞癌 (HCC) 治疗的当前进展。与 HCC 相比，纤维板层 HCC (FL-HCC) 是一种不常见的肿瘤，最常见于没有潜在肝病的青少年或年轻人。 3 基于化疗的方案通常用于治疗 FL-HCC。患者队列和病例系列。3 尽管有传闻称对全身治疗有反应，但晚期 FL-HCC 的预后很差。4 免疫检查点抑制剂 (ICP) 的发展正在彻底改变 HCC 的治疗方法。特别是，最近的试验表明，如果联合使用 ICP，可以加强免疫肿瘤学治疗。 5 6 这以使用纳武单抗/易普利姆玛为例，